Приказ основних података о документу
Synthesis, Characterization, and Therapeutic Efficacy of 177Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
dc.creator | Stanković, Dragana | |
dc.creator | Radović, Magdalena | |
dc.creator | Stanković, Aljoša | |
dc.creator | Mirković, Marija | |
dc.creator | Vukadinović, Aleksandar | |
dc.creator | Mijović, Milica | |
dc.creator | Milanović, Zorana | |
dc.creator | Ognjanović, Miloš | |
dc.creator | Janković, Drina | |
dc.creator | Antić, Bratislav | |
dc.creator | Vranješ-Đurić, Sanja | |
dc.creator | Savić, Miroslav | |
dc.creator | Prijović, Željko | |
dc.date.accessioned | 2023-08-14T11:53:23Z | |
dc.date.available | 2023-08-14T11:53:23Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1999-4923 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/11387 | |
dc.description.abstract | As an alternative to classical brachytherapy, intratumoral injection of radionuclide-labeled nanoparticles (nanobrachytherapy, NBT) has been investigated as a superior delivery method over an intravenous route for radionuclide therapy of solid tumors. We created superparamagnetic iron oxide nanoparticles (SPIONs) coated with meso-1,2-dimercaptosuccinic acid (DMSA) and radiolabeled with Lutetium-177 (177Lu), generating 177Lu-DMSA@SPIONs as a potential antitumor agent for nanobrachytherapy. Efficient radiolabeling of DMSA@SPIONS by 177Lu resulted in a stable bond with minimal leakage in vitro. After an intratumoral injection to mouse colorectal CT-26 or breast 4T1 subcutaneous tumors, the nanoparticles remained well localized at the injection site for weeks, with limited leakage. The dose of 3.70 MBq/100 µg/50 µL of 177Lu-DMSA@SPIONs applied intratumorally resulted in a high therapeutic efficacy, without signs of general toxicity. A decreased dose of 1.85 MBq/100 µg/50 µL still retained therapeutic efficacy, while an increased dose of 9.25 MBq/100 µg/50 µL did not significantly benefit the therapy. Histopathology analysis revealed that the 177Lu-DMSA@SPIONs act within a limited range around the injection site, which explains the good therapeutic efficacy achieved by a single administration of a relatively low dose without the need for increased or repeated dosing. Overall, 177Lu-DMSA@SPIONs are safe and potent agents suitable for intra-tumoral administration for localized tumor radionuclide therapy | en |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200017/RS// | en |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/621375/EU// | en |
dc.relation | COST Action CA [19114] | en |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Pharmaceutics | en |
dc.subject | nanobrachytherapy | en |
dc.subject | nanoparticles | en |
dc.subject | 177Lu | en |
dc.subject | radionuclide therapy | en |
dc.subject | tumor | en |
dc.title | Synthesis, Characterization, and Therapeutic Efficacy of 177Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors | en |
dc.type | article | en |
dc.rights.license | BY | |
dc.citation.volume | 15 | |
dc.citation.issue | 7 | |
dc.citation.spage | 1943 | |
dc.identifier.doi | 10.3390/pharmaceutics15071943 | |
dc.type.version | publishedVersion | |
dc.identifier.scopus | 2-s2.0-85166357209 | |
dc.identifier.fulltext | http://vinar.vin.bg.ac.rs/bitstream/id/31055/pharmaceutics-15-01943.pdf |
Документи
Овај документ се појављује у следећим колекцијама
-
Radovi istraživača
Researchers' publications